DANIEL LYNCH Insider Trading $BPMC Blueprint Medicines Corp
Get free email notifications about insider trading for DANIEL LYNCH.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of DANIEL LYNCH. DANIEL LYNCH is Acting Chief Executive Officer in IMCLONE SYSTEMS INC ($IMCLE) and Chief Executive Officer in IMCLONE SYSTEMS INC ($IMCLE) and in bluebird bio, Inc. ($BLUE) and Director in bluebird bio, Inc. ($BLUE) and Director in BIND Therapeutics, Inc ($BIND) and Director in Eleven Biotherapeutics, Inc. ($EBIO) and Director in Blueprint Medicines Corp ($BPMC) and Director in Translate Bio, Inc. ($TBIO) and Director in Surface Oncology, Inc. ($SURF) and Director in SpringWorks Therapeutics, Inc. ($SWTX).
DANIEL LYNCH in Blueprint Medicines Corp
Trading Symbol: BPMCIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of DANIEL LYNCH: Director
Holdings: 127,904 shares
Current Value: $4,584,079
Latest Transaction: Jun 26 2020
$BPMC Market Capitalization: $979.55M
$BPMC Previous Close: $35.84
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of DANIEL LYNCH in Blueprint Medicines Corp
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, BLUE, BPMC, BIND, IMCLE, SESN, SWTX, SURF, TBIO
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 26 2020 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 76.24 | 4,500 | 343,080 | 4,500 | |
Jun 26 2020 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Grant | A | 0.00 | 2,250 | 0 | 127,904 | 125.7 K to 127.9 K (+1.79 %) |
Jun 23 2020 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | M | 0.00 | 1,312 | 0 | 0 | |
Jun 23 2020 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Buy | M | 0.00 | 1,312 | 0 | 125,654 | 124.3 K to 125.7 K (+1.06 %) |
Apr 07 2020 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Gift | G | 0.00 | 50,000 | 0 | 124,342 | 174.3 K to 124.3 K (-28.68 %) |
Jun 20 2019 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 0.00 | 1,312 | 0 | 1,312 | |
Jun 20 2019 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 96.77 | 4,875 | 471,754 | 4,875 | |
Jun 25 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 69.79 | 7,500 | 523,425 | 29,318 | |
Feb 16 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 80.42 | 12,500 | 1,005,250 | 174,342 | 186.8 K to 174.3 K (-6.69 %) |
Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 73.27 | 3,996 | 292,787 | 186,842 | 190.8 K to 186.8 K (-2.09 %) |
Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 74.31 | 3,748 | 278,514 | 190,838 | 194.6 K to 190.8 K (-1.93 %) |
Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 75.15 | 5,636 | 423,545 | 194,586 | 200.2 K to 194.6 K (-2.81 %) |
Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 75.96 | 2,590 | 196,736 | 200,222 | 202.8 K to 200.2 K (-1.28 %) |
Feb 14 2018 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 77.18 | 1,530 | 118,085 | 202,812 | 204.3 K to 202.8 K (-0.75 %) |
Nov 17 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 62.59 | 1,200 | 75,108 | 204,342 | 205.5 K to 204.3 K (-0.58 %) |
Nov 17 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 63.25 | 2,200 | 139,150 | 205,542 | 207.7 K to 205.5 K (-1.06 %) |
Nov 17 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 64.15 | 1,600 | 102,640 | 207,742 | 209.3 K to 207.7 K (-0.76 %) |
Sep 20 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 60.00 | 2,500 | 150,000 | 209,342 | 211.8 K to 209.3 K (-1.18 %) |
Jul 07 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 55.06 | 7,500 | 412,950 | 211,842 | 219.3 K to 211.8 K (-3.42 %) |
Jun 30 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 49.09 | 3,125 | 153,406 | 219,342 | 222.5 K to 219.3 K (-1.40 %) |
Jun 30 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 50.12 | 21,474 | 1,076,277 | 222,467 | 243.9 K to 222.5 K (-8.80 %) |
Jun 30 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 51.17 | 7,901 | 404,294 | 243,941 | 251.8 K to 243.9 K (-3.14 %) |
Jun 23 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 46.02 | 10,909 | 502,032 | 21,818 | |
Mar 16 2017 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 40.12 | 7,500 | 300,900 | 250,119 | 257.6 K to 250.1 K (-2.91 %) |
Dec 05 2016 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 30.02 | 200 | 6,004 | 255,694 | 255.9 K to 255.7 K (-0.08 %) |
Nov 03 2016 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 30.04 | 1,700 | 51,068 | 255,894 | 257.6 K to 255.9 K (-0.66 %) |
Oct 17 2016 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Sell | S | 30.02 | 21,800 | 654,436 | 257,594 | 279.4 K to 257.6 K (-7.80 %) |
Jun 27 2016 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Option Exercise | A | 19.53 | 10,909 | 213,053 | 10,909 | |
Dec 02 2015 | BPMC | Blueprint Medicine ... | LYNCH DANIEL | Director | Buy | J | 0.00 | 2,517 | 0 | 275,244 | 272.7 K to 275.2 K (+0.92 %) |
Page: 1